This grant supports research on the development of monoclonal antibodies to prevent and treat infections caused by Flaviviruses, such as Dengue Virus, Tick-borne Encephalitis Virus, Japanese Encephalitis Virus, West Nile Fever Virus, Yellow Fever Virus, and Zika Virus. The aim is to expand prophylactic and therapeutic options, strengthen preparedness for future infectious disease outbreaks, and reinforce the EU’s leading role in research and innovation related to health security.
| Agency | HORIZON (EU) |
|---|---|
| Region | EUUSAother |
| Country | N/A |
| Legal form | Company, NGO, Government organization, Other |
| Start date | 10 Feb 2027 |
| End date | 13 Apr 2027 |
| Max funding | EUR 9,000,000 - 10,000,000 per project |
| Budget | EUR 37,300,000 (2027 call total budget) |
| Coverage | Funding rate: up to 100% of eligible costs for eligible applicants |